Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04546763 · ClinicalTrials.gov registry record
Study Watch AF Detection At Home
A clinical trial, sponsored by Verily Life Sciences.
- Completed
- Registry status
- 117
- Enrollment target
NCT04546763: Completed study, sponsored by Verily Life Sciences.
NCT04546763 is a clinical trial that has completed, run by Verily Life Sciences. The registered enrollment target is 117 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04546763 has completed, sponsored by Verily Life Sciences.
- COMPLETED
- Registry status
- 117 participants
- Enrollment target
Study Summary
This is a multi-center, prospective, non-randomized study to evaluate the performance of the study watch PPG algorithm in detecting irregular rhythms suggestive of atrial fibrillation (AF) in subjects at risk of having an event of AF in the free living (home) environment.
Primary Outcome
Accuracy of AF detection based on sensitivity observed in a 14-day followup period
Interventions
- DEVICE Study Watch
- DEVICE Zio XT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2020-09-03 |
| Est. Completion | 2021-05-14 |
What the finished NCT04546763 record still lists
NCT04546763 is an observational study that tracks outcomes without assigning an intervention. The registered 117 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Study Watch is the first listed.
NCT04546763 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04546763 about?
NCT04546763 is a clinical study titled "Study Watch AF Detection At Home". This is a multi-center, prospective, non-randomized study to evaluate the performance of the study watch PPG algorithm in detecting irregular rhythms suggestive of atrial fibrillation (AF) in subjects at risk of having an event of AF in the free living (home) environment.
What is the current status of trial NCT04546763?
This trial is currently completed. The enrollment target is 117 participants. The study started on 2020-09-03. Estimated completion is 2021-05-14.
What interventions are being tested in trial NCT04546763?
The interventions under investigation include: Study Watch (DEVICE), Zio XT (DEVICE).
Who is sponsoring clinical trial NCT04546763?
This trial is sponsored by Verily Life Sciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03539822 · 117 participants · Phase 1
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
- NCT03786692 · 117 participants · Phase 2
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
- NCT04479696 · 117 participants · NA
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors
- NCT04940585 · 117 participants · NA
ROSE in Sunset Park
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI